Crossmark

Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis

Crossref DOI link: https://doi.org/10.1007/s13555-025-01647-0

Published Online: 2026-01-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pink, Andrew E.

Houghton, John

White, Holly

Schiavo, Sofia

Piketty, Christophe

Ulianov, Liliana

Rout, Rajesh

Jack, Katrin

Subramanian, Ramkumar

Puelles, Jorge https://orcid.org/0000-0003-3493-1252
License Information

Text and Data Mining valid from 2026-01-19

Version of Record valid from 2026-01-19
More Information

Article History

Received: 17 October 2025

Accepted: 22 December 2025

First Online: 19 January 2026

Declarations

:

: Andrew Pink has acted as an advisory board member for, investigator for, received grants from, or received educational support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen J&J, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Galderma, Pfizer, Sanofi and UCB. Christophe Piketty, Liliana Ulianov, Rajesh Rout, Katrin Jack, Ramkumar Subramanian and Jorge Puelles are employees of Galderma Ltd. John Houghton, Holly White and Sofia Schiavo are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd received fees from Galderma Ltd in relation to this study.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below